RE: Cost efficient company and mega AI results4 Dec 2025 16:42
As Anthony alluded too, Nutt may be picking up that phone and awful lot.
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is delighted to announce amendments to its consultancy agreement with Professor David Nutt, the Company's Chief Scientific Officer. Under the revised terms, Professor Nutt will increase his commitment to Solvonis, serve as Interim Chair of the newly established Scientific Advisory Committee ("SAC"), and work exclusively with the Company in the field of commercial drug discovery and development for CNS disorders.
I also suggest people listen to the recent roast podcast.